drug protocol number

ID-076A301 / SOS-AMI

drug sponsor

Viatris Innovation GmbH / IQVIA

drug study

(ACT-246475) is a 2-phenyl-pyrimidine derivative selatogrel

drug trial site

King Faisal Specialist Hospital and Research Center (Riyadh),King Saud University Medical City (Riyadh), King Fahad Specialist Hospital (Dammam),King Abdulaziz Medical City NG (Riyadh), King Abdulaziz Medical City NG (Jeddah)

drug status

Ongoing

drug phase